Anthocyanins potentiate the activity of trastuzumab in human epidermal growth factor receptor 2positive breast cancer cells in vitro and in vivo

By              

Molecular Medicine Reports, Vol. 10, Iss. 4, 2014-01 ,pp. : 1921-1926

Spandidos Publications

Access to resources Recommend Favorite

Adding hormonal therapy to chemotherapy and trastuzumab improves prognosis in patients with hormone receptor-positive and human epidermal growth factor receptor 2-positive primary breast cancer

By Hayashi Naoki  

Breast Cancer Research and Treatment, Vol. 137, Iss. 2, 2013-01 ,pp. : 523-531

Springer Publishing Company

Access to resources Recommend Favorite

Lapatinib combined with neoadjuvant paclitaxel-trastuzumab-based chemotherapy in patients with human epidermal growth factor receptor 2-positive breast cancer: A meta-analysis of randomized controlled trials

By  

Oncology Letters, Vol. 9, Iss. 3, 2015-01 ,pp. : 1351-1358

Spandidos Publications

Access to resources Recommend Favorite

Pertuzumab for the treatment of patients with human epidermal growth factor receptor 2positive breast cancer in Japan

By        

Molecular and Clinical Oncology, Vol. 3, Iss. 6, 2015-01 ,pp. : 1268-1274

Science Publishers

Access to resources Recommend Favorite

Serum epidermal growth factor is associated with prognosis and hormone receptor status in patients with HER2-positive metastatic breast cancer treated with first-line trastuzumab plus taxane chemotherapy

By Kim Ji-Won   Kim Jee   Im Seock-Ah   Lee Kyung-Hun   Kim Jin-Soo   Kim Tae-Yong   Han Sae-Won   Jeon Yoon   Oh Do-Youn   Kim Tae-You   Park In  

Cancer Chemotherapy and Pharmacology, Vol. 72, Iss. 5, 2013-11 ,pp. : 1023-1029

Springer Publishing Company

Access to resources Recommend Favorite